Retatrutide Prescribed Online to Maine Residents
Medical Weight Loss Treatment in Maine
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Maine
Maine's rugged beauty extends from Portland's vibrant waterfront to the remote forests of Aroostook County. OmniRx Health serves this diverse landscape—connecting lobstermen on the coast, ski resort workers in the mountains, and retirees seeking the quiet life with expert medical care. Our telehealth platform eliminates the long drives that Maine's geography often requires, bringing healthcare as close as your living room in the Pine Tree State.
OmniRx Health providers are licensed by the Maine Board of Licensure in Medicine to serve patients throughout the Pine Tree State.
Maine pharmacies in Portland, Bangor, Augusta, and coastal communities provide prescription services with delivery to all corners of the state.
Maine has progressive telehealth laws that address the unique needs of its rural and island communities, ensuring virtual care access statewide.
Maine requires insurers to cover telehealth services at parity with in-person care, making virtual visits accessible and affordable.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Maine?
- Yes, Maine fully supports telehealth with laws designed to serve its rural population. Licensed providers can offer comprehensive virtual care including prescriptions and ongoing treatment.
- Can Maine's island residents use telehealth?
- Absolutely. Telehealth is ideal for Maine's island communities where mainland healthcare access requires ferry travel. Our platform brings specialist care directly to you.
- How does telehealth help Maine's aging population?
- Telehealth reduces travel burden for older Mainers, providing convenient access to care without navigating winter roads or making long drives to medical centers.